Conceptual model of pharmaceutical care for patients with coronary heart disease and comorbid conditions in Ukraine

<b>Background:</b> According to WHO's data, a significant number of deaths from CVD is observed in Ukraine. In today's conditions, the problems of ensuring the availability of medicines and pharmaceutical care for patients with CHD and comorbid conditions are being addressed at all levels of management of the Ukrainian healthcare sector in conditions of limited funds, resources and martial law. The scientific development of a conceptual model for providing pharmaceutical care to such patients, aimed at reducing the burden on the healthcare system and ensuring the safe use of medicines in compliance with European legislation, is highly relevant. <b>Methods:</b> The methods used in this work include information retrieval, analysis, synthesis, generalisation, induction and deduction, synergistic, dialectical, and modelling. <b>Results:</b> The conceptual model of pharmaceutical care for patients with CHD and comorbid conditions was developed and substantiated. The place and role of pharmacists in the context of participation in interprofessional collaboration in multidisciplinary teams is defined. The rationale for involving pharmacists in multidisciplinary teams has been substantiated, as this will enhance the quality of personalised care, prevent potential medicines interactions considering their metabolic profiles, reduce the risk of adverse reactions and improve patient adherence to pharmacotherapy. <b>Conclusion:</b> The model of pharmaceutical care for patients with CHD and comorbid conditions takes into account the cardiovascular continuum and pharmacotherapy, which will lead to a decrease in disease progression, pharmacotherapeutic risks, reduce the burden on the healthcare system and guarantee the safety of medicines use. Implementation of the conceptual model of pharmaceutical care for patients with CHD and comorbid conditions in pharmaceutical practice requires revision of educational training programmes.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Policy and Practice
Published
2025-04-08
DOI
https://doi.org/10.1080/20523211.2025.2484577
Citations
4
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
12.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Conceptual model of pharmaceutical care for patients with coronary heart disease and comorbid conditions in Ukraine

Н. А. Білоусова
4 citations
Journal of Pharmaceutical Policy and Practice
Pharmaceutical Economics and Policy
12.52
article

Conceptual model of pharmaceutical care for patients with coronary heart disease and comorbid conditions in Ukraine

Н. А. Білоусова
article en
4 citations

Abstract

<b>Background:</b> According to WHO's data, a significant number of deaths from CVD is observed in Ukraine. In today's conditions, the problems of ensuring the availability of medicines and pharmaceutical care for patients with CHD and comorbid conditions are being addressed at all levels of management of the Ukrainian healthcare sector in conditions of limited funds, resources and martial law. The scientific development of a conceptual model for providing pharmaceutical care to such patients, aimed at reducing the burden on the healthcare system and ensuring the safe use of medicines in compliance with European legislation, is highly relevant. <b>Methods:</b> The methods used in this work include information retrieval, analysis, synthesis, generalisation, induction and deduction, synergistic, dialectical, and modelling. <b>Results:</b> The conceptual model of pharmaceutical care for patients with CHD and comorbid conditions was developed and substantiated. The place and role of pharmacists in the context of participation in interprofessional collaboration in multidisciplinary teams is defined. The rationale for involving pharmacists in multidisciplinary teams has been substantiated, as this will enhance the quality of personalised care, prevent potential medicines interactions considering their metabolic profiles, reduce the risk of adverse reactions and improve patient adherence to pharmacotherapy. <b>Conclusion:</b> The model of pharmaceutical care for patients with CHD and comorbid conditions takes into account the cardiovascular continuum and pharmacotherapy, which will lead to a decrease in disease progression, pharmacotherapeutic risks, reduce the burden on the healthcare system and guarantee the safety of medicines use. Implementation of the conceptual model of pharmaceutical care for patients with CHD and comorbid conditions in pharmaceutical practice requires revision of educational training programmes.

Journal of Pharmaceutical Policy and PracticeVol. 18(1)
Shupyk National Healthcare University of Ukraine (UA)
American Diabetes Association, European Society of Cardiology
Good health and well-being
Openalex Percentile: Top 2%
Pharmaceutical Economics and Policy
12.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.